• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
XERS

XERS

Xeris Biopharma Holdings, Inc.

NASDAQHealthcareBiotechnologyUS

USD5.89

-0.11 (-1.83%)

Rating:C+

Company Profile

CEO

John Shannon

IPO Date

2018-06-21

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$5.99

Prev. Close

$6.00

Day Low

$5.81

Day High

$5.99

52W Low

$4.30

52W High

$10.08

Market Cap

$1.02B

Volume

1.15M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentNeutral

Articles

10

Avg Positive

19.2%

Avg Negative

18.7%

Avg Neutral

62.4%

News Feed

Xeris Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021

Business Wire·7/29/2021·↑ positive

Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in Europe

Business Wire·7/19/2021·↑ positive

Implied Volatility Surging for Xeris Pharmaceuticals (XERS) Stock Options

Zacks Investment Research·6/16/2021·↓ negative

Reddit Stocks: What Are Top Meme Stocks AMC, GME and BB Doing Today?

InvestorPlace·6/4/2021·↓ negative

Get Ready for a XERS Stock Squeeze! Why One Analyst Thinks Xeris Could Be the Next AMC

InvestorPlace·6/3/2021·↑ positive

STRONGBRIDGE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Strongbridge Biopharma plc - SBBP

Business Wire·5/28/2021·↓ negative

Xeris Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Xeris Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – XERS

Business Wire·5/24/2021·↑ positive

SHAREHOLDER ALERT: WeissLaw LLP Investigates Strongbridge Biopharma plc

PRNewsWire·5/24/2021·↓ negative

Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases

PRNewsWire·5/24/2021·↑ positive

Xeris Pharmaceuticals: Strong Growth In COVID-19 Headwinds Leads To Unjustified Sell-Off

Seeking Alpha·5/17/2021·↓ negative